The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
BioHarvest Sciences Inc. (NASDAQ: BHST) reported full-year 2025 revenue of $34.5 million, marking a 37% increase over the previous year. In the fourth quarter, the company posted a loss of $0.10 per share, outperforming the Zacks Consensus Estimate of a $0.11 loss. This performance reflects a significant year-over-year improvement from the $0.17 loss per share recorded in the same period last year. While quarterly revenue figures lagged behind analyst expectations, the company's overall trajectory remains focused on narrowing net losses through improved operational efficiency. Strategic investments in core product segments and contract manufacturing continue to drive margin expansion. Management highlighted that these results underscore the company's progress toward achieving sustainable profitability in the biotech sector.
Sign up free to access this content
Create Free Account